The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
23:00
Former German ambassador to Tel Aviv criticizes Israeli colonization in the West Bank: "We need to clarify what we want to say when we rightly affirm that we support Israel."
22:52
Two media groups in the USA have filed a lawsuit against the sale of priority access to Donald Trump's posts on Truth Social, considering the system to be corrupt and unconstitutional.
22:45
SBU announces that Ukrainian forces attacked the Russian naval base at Novorossiisk, destroying three warships. The attack took place on the night from Tuesday to Wednesday.
22:41
A non-profit organization from Berlin has filed a criminal complaint against Meta's smart glasses, accusing them of violating privacy regulations in Germany.
22:32
The Israeli Minister of Defense stated that he will not withdraw from the security zones in Lebanon, Syria, and the Gaza Strip, continuing operations against Hezbollah.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
